Review of: "The Application and Pathway Regulation of Traditional Chinese Medicine in Lung Cancer Treatment: An Exploratory Review"

Muhammad Harith Zulkifli[1]

1 Universiti Teknologi Mara

Thank you for the opportunity to review the manuscript. Below are my comments for improvement.

a. Abstract & Introduction:

1. Generally, there are two types of lung cancer: small cell lung cancer and non-small cell lung cancer. It is not clear why the author only focuses on the latter one.
2. The author wrote, "Although treatments such as surgery, radiotherapy, targeted therapy, and immunotherapy have achieved better clinical efficacy…" but there is no comparison to be made.

b. NF-κB Signaling Pathway section:

1. It is suggested that the author can provide a figure to show the components of the NF-κB signaling pathway and its relationship with NSCLC.
2. The author wrote, "NF-κB signaling pathway is divided into three types: the classical pathway, the non-classical pathway, and other pathways," but the "other pathways" were not discussed in the manuscript.
3. Despite emphasizing the advantages of traditional Chinese medicine (TCM) from a multitarget perspective compared to conventional treatment, this was not sufficiently addressed and discussed by the author.
4. There was no reference cited with regards to the explanation of resveratrol and artemisinin.

MAPK Signaling Pathway section:

1. Same comments as above.

Monomeric Traditional Chinese Medicine Reversing Multidrug Resistance in NSCLC and
Its Mechanisms section:

1. Same comments as above.
2. It is not clear why the author put specific sections for monomeric components. The author should define the meaning of monomeric components.

Conclusion:

1. None.